OncoMatch/Pancreatic Cancer (PDAC)/BRCA1
Pancreatic Cancer (PDAC)BRCA1 Clinical Trials
Germline BRCA1 pathogenic variants occur in approximately 1–3% of pancreatic ductal adenocarcinoma (PDAC) and confer sensitivity to platinum-based chemotherapy and PARP inhibition through homologous recombination deficiency. Olaparib maintenance after platinum-based induction is FDA-approved for germline BRCA1/2-positive metastatic PDAC. Trials explore PARP inhibitor combinations with ATR/CHK1 inhibitors and immunotherapy, and somatic BRCA1 alteration eligibility.
Top recruiting BRCA1 Pancreatic Cancer (PDAC) trials
Ranked by phase and US site count.
See all trials matched to your profile →The Cancer of the Pancreas Screening-5 CAPS5)Study
Johns Hopkins University
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
AstraZeneca
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Exelixis
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
Dana-Farber Cancer Institute
Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Combination Therapy in Cancers With Mutations in DNA Repair Genes
University of California, San Francisco